| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Vasopressin V1 receptor[1]
Vasopressin V1 receptor. Terlipressin diacetate is a highly selective vasopressin V1 receptor agonist. It is an analog of vasopressin and a partial agonist of the vasopressin V1A receptor with a Ki of 0.85 µM. By activating the V1 receptor, it induces vasoconstriction, reduces splanchnic blood flow, and decreases portal pressure. |
|---|---|
| ln Vitro |
Treatment of IEC-6 cells with terlipressin diacetate (25 nM; 24-72 hours) greatly enhanced cell viability, proliferation, and apoptosis [1]. After OGD/R (oxygen and glucose deprivation), terlipressin diacetate inhibits the secretion of TNF-α and 15-F2t-isoprostane in IEC-6 cells. Through the PI3K signaling pathway, terlipressin diacetate given after OGD can lessen OGD/R-induced cell damage [1].
Terlipressin diacetate is a highly selective V1 receptor agonist that reduces splanchnic blood flow and portal pressure. It has anti-inflammatory and antioxidant effects. As a vasopressin analog, it would be expected to induce vasoconstriction and antidiuretic effects through V1 and V2 receptor activation, with selectivity for the V1 receptor. |
| ln Vivo |
In a mouse model of non-lethal hepatic ischemia-reperfusion (IR), terlipressin diacetate treatment markedly alleviated hepatocyte apoptosis, necrosis, and inflammation caused by IR [3].
In vivo, Terlipressin diacetate is used as a vasoactive drug in the management of low blood pressure. It controls acute variceal bleeding by reducing splanchnic blood flow and portal pressure. It is also being studied for hepatorenal syndrome and norepinephrine-resistant septic shock. Its vasoconstrictive and anti-inflammatory effects contribute to its therapeutic actions. |
| Enzyme Assay |
In vitro receptor binding assays are used to characterize Terlipressin diacetate as a V1 receptor agonist. Radioligand binding assays are performed using membranes from cells expressing the V1 receptor, and the compound's ability to displace a labeled V1 ligand is measured to determine its binding affinity (Ki of 0.85 µM).
|
| Cell Assay |
Cell Proliferation Assay[1]
Cell Types: IEC-6 cells induced by oxygen and glucose deprivation/re-oxygenation (OGD/R) Tested Concentrations: 25 nM Incubation Duration: 24 hrs (hours), 48 hrs (hours), 72 hrs (hours) Experimental Results: Dramatically increased the proliferation of IEC-6 cells. Cellular assays for Terlipressin diacetate involve treating V1 receptor-expressing cells with the compound and measuring receptor activation. Functional readouts include intracellular calcium mobilization, which is a key downstream signal following V1 receptor activation. These assays confirm the compound's agonistic activity at the V1 receptor. |
| Animal Protocol |
In vivo efficacy of Terlipressin diacetate is evaluated in animal models of portal hypertension and bleeding. The compound is administered via injection, and its effects on portal pressure, splanchnic blood flow, and bleeding control are assessed. Its vasoconstrictive and anti-inflammatory effects are also studied in models of septic shock and hepatorenal syndrome.
|
| ADME/Pharmacokinetics |
Terlipressin diacetate is a peptide with molecular formula C56H82N16O19S2 and molecular weight of 1347.48. It is soluble in DMSO (≥49.9 mg/mL), ethanol (≥4.83 mg/mL), and water (≥44.6 mg/mL). As a peptide, its pharmacokinetic properties would be characteristic of this class, with a short half-life. It is typically administered via injection.
|
| Toxicity/Toxicokinetics |
No specific toxicity data is available for Terlipressin diacetate. As a vasopressin analog and V1 receptor agonist, its safety profile would be related to its pharmacological effects, including vasoconstriction and potential for ischemia. Standard preclinical safety studies would be required to evaluate its safety for therapeutic applications.
|
| References | |
| Additional Infomation |
See also: terlipressin (in salt form).
Terlipressin diacetate (CAS#: 1884420-36-3) is a vasoactive vasopressin analog and highly selective V1 receptor agonist. It reduces splanchnic blood flow and portal pressure and controls acute variceal bleeding. It has anti-inflammatory and antioxidant effects. It has a molecular formula of C56H82N16O19S2 and a molecular weight of 1347.48. |
| Molecular Formula |
C56H82N16O19S2
|
|---|---|
| Molecular Weight |
1347.48
|
| Exact Mass |
1346.538
|
| CAS # |
1884420-36-3
|
| Related CAS # |
Terlipressin;14636-12-5;Terlipressin acetate;914453-96-6
|
| PubChem CID |
72941948
|
| Sequence |
H-Gly-Gly-Gly-Cys(1)-Tyr-Phe-Gln-Asn-Cys(1)-Pro-Lys-Gly-NH2.2CH3CO2H
glycyl-glycyl-glycyl-L-cysteinyl-L-tyrosyl-L-phenylalanyl-L-glutaminyl-L-asparagyl-L-cysteinyl-L-prolyl-L-lysyl-glycinamide (4->9)-disulfide acetic acid |
| SequenceShortening |
GGGCYFQNCPKG
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
18
|
| Hydrogen Bond Acceptor Count |
23
|
| Rotatable Bond Count |
25
|
| Heavy Atom Count |
93
|
| Complexity |
2410
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
CC(=O)O.CC(=O)O.C1C[C@H](N(C1)C(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)NC(=O)CNC(=O)CNC(=O)CN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N
|
| InChi Key |
WNFVFDPQEHRNTC-LWCZBKQBSA-N
|
| InChi Code |
InChI=1S/C52H74N16O15S2.2C2H4O2/c53-17-5-4-9-31(45(76)60-23-41(57)72)63-51(82)38-10-6-18-68(38)52(83)37-27-85-84-26-36(61-44(75)25-59-43(74)24-58-42(73)22-54)50(81)65-34(20-29-11-13-30(69)14-12-29)48(79)64-33(19-28-7-2-1-3-8-28)47(78)62-32(15-16-39(55)70)46(77)66-35(21-40(56)71)49(80)67-37;2*1-2(3)4/h1-3,7-8,11-14,31-38,69H,4-6,9-10,15-27,53-54H2,(H2,55,70)(H2,56,71)(H2,57,72)(H,58,73)(H,59,74)(H,60,76)(H,61,75)(H,62,78)(H,63,82)(H,64,79)(H,65,81)(H,66,77)(H,67,80);2*1H3,(H,3,4)/t31-,32-,33-,34-,35-,36-,37-,38-;;/m0../s1
|
| Chemical Name |
acetic acid;(2S)-1-[(4R,7S,10S,13S,16S,19R)-19-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[(2S)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]pyrrolidine-2-carboxamide
|
| Synonyms |
Terlipressin diacetate salt; Terlipressin di-acetate; CHEMBL4088899; 1884420-36-3; Terlipressin acetate salt; 14636-12-5free base;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: 100 mg/mL (74.2 mM)
DMSO: 50 mg/mL (37.1 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (1.86 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (1.86 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. View More
Solubility in Formulation 3: 100 mg/mL (74.21 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.7421 mL | 3.7106 mL | 7.4213 mL | |
| 5 mM | 0.1484 mL | 0.7421 mL | 1.4843 mL | |
| 10 mM | 0.0742 mL | 0.3711 mL | 0.7421 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
